Ariosa Diagnostics, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Ariosa Diagnostics, Inc.
At Solicitor General’s Urging, Supreme Court May Take Up Patent Eligibility Dispute Riling Biopharma
Federal Circuit’s rulings on subject matter patent eligibility have fractured the court, the US government says in advising the high court to review American Axle v. Neapco to provide clarity. BIO, former PTO director Kappos and Sen. Tillis also urge Supreme Court to hear the case.
US PTO's Patent Eligibility Guidance Draws Industry Plaudits, Request For More Specifics
BIO, PhRMA, Novartis, Amgen, and Genentech suggest revisions to guidance on hot-button issue of subject matter patent eligiblity; patent owners group says 'best approach' is to enact legislation to restore patent eligibility law.
Illumina Awarded $26.7m In Patent Row
The verdict resolves an intellectual property dispute in which Illumina alleged Ariosa was violating Illumina's patents on prenatal genetic testing technology.
Roche Eyes Liquid Biopsy As A Boost To Drug Development, Cancer Monitoring
Roche Molecular Diagnostic's top researcher, Walter Koch, discusses the promise of liquid biopsy following FDA's recent approval of its first liquid-biopsy companion diagnostic, Roche's cobas test for the cancer drug Tarceva.
- Other Names / Subsidiaries
- Aria Diagnostics
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.